药学学报, 2014, 49(10): 1426-1432
引用本文:
谢诚, 丁肖梁, 薛领, 蒋彬, 杭永付, 高杰, 缪丽燕. 急性冠脉综合征患者氯吡格雷群体药动学-药效学结合模型研究[J]. 药学学报, 2014, 49(10): 1426-1432.
XIE Cheng, DING Xiao-liang, XUE Ling, JIANG Bin, HANG Yong-fu, GAO Jie, MIAO Li-yan. Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome[J]. Acta Pharmaceutica Sinica, 2014, 49(10): 1426-1432.

急性冠脉综合征患者氯吡格雷群体药动学-药效学结合模型研究
谢诚1, 丁肖梁1, 薛领1, 蒋彬2, 杭永付1, 高杰1, 缪丽燕1
1. 苏州大学附属第一医院 药学部, 江苏 苏州 215006;
2. 苏州大学附属第一医院 心血管内科, 江苏 苏州 215006
摘要:
本研究旨在急性冠脉综合征患者中建立氯吡格雷的群体药动学-药效学模型。通过前瞻性收集59例急性冠脉综合征患者,分别以氯吡格雷活性硫醇代谢产物和血小板VASP磷酸化水平作为其药动学和药效学指标,同时考察人口学指标、实验室指标、合并用药、临床合并症和相关代谢酶的遗传变异等因素,运用NONMEM软件对数据进行分析。药动学模型选择一般线性模型作为基础模型拟合数据,药效学模型选择间接效应模型- Turnover模型作为基础模型拟合数据。结果表明,氯吡格雷原药到活性硫醇代谢产物前体转化参数K12、活性硫醇代谢产物表观清除率(CL/F)和表观分布容积(V/F)的群体典型值分别为0.259 h-1、179 L·h-1和632 L,达最大药效一半时药效学参数EC50、药效生成参数Kin和最大药效参数Emax的群体典型值分别为1.57 ng·mL-1、4.29和0.664。最终模型显示,CYP2C19基因多态性对药动学模型中原药到活性硫醇代谢产物前体转化参数K12有影响,对临床合理使用氯吡格雷具有一定的参考意义。
关键词:    氯吡格雷      急性冠脉综合征      群体药动学      群体药效学     
Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome
XIE Cheng1, DING Xiao-liang1, XUE Ling1, JIANG Bin2, HANG Yong-fu1, GAO Jie1, MIAO Li-yan1
1. Department of Pharmacy, The First Affiliated Hospital of Soochow University, Suzhou 215006, China;
2. Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
Abstract:
This study established a population pharmacokinetics-pharmacodynamics model of clopidogrel in patients with acute coronary syndrome. Fifty-nine patients were enrolled. The plasma concentration of clopidogrel active metabolite and vasodilator stimulated phosphoprotein platelet reactivity index (VASP-PRI) were selected as the pharmacokinetics index and the pharmacodynamics index, respectively. The covariates including demographic characteristics, laboratory indexes, combined medication, complications and genetic polymorphisms of related enzymes were screened for their influence on th0e pharmacokinetic and pharmacodynamics parameters. Population pharmacokinetic and pharmacodynamics data analysis was performed using NONMEM software. The general linear model and the indirectly effect model-turnover model for pharmacokinetic and pharmacodynamic analysis were selected as the basic model, respectively. The population typical values of K12, CL/F, V/F, EC50, Ein and Emax were 0.259 h-1, 179 L·h-1, 632 L, 1.57 ng·mL-1, 4.29 and 0.664, respectively. CYP2C19 was the covariate in the final pharmacokinetic model, and the model was to design a prior dosage regimen.
Key words:    clopidogrel    acute coronary syndrome    population pharmacokinetics    population pharmacodynamics   
收稿日期: 2014-03-03
基金项目: 国家自然科学基金资助项目(81173132);江苏省医学重点人才资助项目(RC2011110);苏州市科技计划资助项目(SYS2011137)
通讯作者: 缪丽燕,Tel/Fax:86-512-67780040,E-mail:miaolysuzhou@163.com
Email: miaolysuzhou@163.com
相关功能
PDF(422KB) Free
打印本文
0
作者相关文章
谢诚  在本刊中的所有文章
丁肖梁  在本刊中的所有文章
薛领  在本刊中的所有文章
蒋彬  在本刊中的所有文章
杭永付  在本刊中的所有文章
高杰  在本刊中的所有文章
缪丽燕  在本刊中的所有文章

参考文献:
[1] Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway [J]. Pharmacogenet Genomics, 2010, 20: 463-465.
[2] Chinese Society of Cardiology. Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation [J]. Chin J Cardiol (中华心血管病杂志), 2012, 40: 353-367.
[3] Chinese Society of Cardiology. Guidelines for the management of percutaneous coronary intervention [J]. Chin J Cardiol (中华心血管病杂志), 2012, 40: 271-278.
[4] Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [J]. Eur Heart J, 2012, 33: 2569-2619.
[5] O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction [J]. J Am Coll Cardiol, 2013, 61: 78-140.
[6] Lee J, Hwang YH, Kang WK, et al. Population pharmacokinetic/ pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients [J]. J Clin Pharmacol, 2012, 52: 985-995.
[7] Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases [J]. J Thromb Haemost, 2005, 3: 85-92.
[8] Ding XL, Deng YL, Zhang J, et al. Mutation-sensitive molecular switch method to detect CES1A2 mutation in the Chinese Han and Yao populations [J]. Genet Test Mol Biomarkers, 2011, 15: 659-662.
[9] Ernest II CS, Small DS, Rohatagi S, et al. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease [J]. J Pharmacokinet Pharmacodyn, 2008, 35: 593-618.
[10] Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies [J]. Ann Pharmacother, 2004, 38: 2136-2144.
[11] Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004 [J]. Clin Pharmacokinet, 2007, 46: 221-234.
[12] Xue L, Rui JZ, Zhang Y, et al. Population pharmacokinetic study of tacrolimus in patients with hematopoietic stem cell transplant [J]. Acta Pharm Sin (药学学报), 2009, 44: 1145-1151.
[13] Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel [J]. N Engl J Med, 2009, 360: 354-362.
[14] Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study [J]. Lancet, 2009, 373: 309-317.
[15] Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention [J]. Eur Heart J, 2009, 30: 916-922.
[16] Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis [J]. Am J Cardiol, 2009, 103: 806-811.
[17] Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American college of cardiology foundation task force on clinical expert consensus documents and the American heart association [J]. Circulation, 2010, 122: 537-557.
相关文献:
1.芮建中;杨友春;王亦流1;陈刚.硫酸镁治疗妊娠高血压综合征的群体药动学—药效学[J]. 药学学报, 1996,31(2): 81-85